Mustafa GÜLER, Saadet YAZGAN UMUT, Teoman AYDIN, Aylin REZVANİ, Emine POYRAZ

The correlation between cardiovascular risk and functional disability and disease activity in the patients with rheumatoid arthritis

To determine the cardiovascular risk (CVR) in patients with rheumatoid arthritis (RA) and its correlation with disease activity and functional ability by using the Framingham risk score (FRS) and to compare the CVR of the RA patients with the control group with the help of the FRS. Materials and methods: Seventy-four RA patients, who were in conformity with the criteria of the American College of Rheumatology, were included in this study at Bezmialem Vakıf University Hospital. A total of 39 subjects without inflammatory arthritis were included as the control group. The FRS was calculated by evaluating age, smoking habits, diabetes, cholesterol and blood pressure measurements. The disease activity score-28 (DAS-28) and the health assessment questionnaire (HAQ-DI) were applied to the RA patients. Results: We could not find any significant difference between the case and control groups in terms of FRS. The means of erythrocyte sedimentation rate (ESR) and blood pressure of participants in the study group were significantly higher than those of the control group. There was not any significant difference in terms of C-reactive protein (CRP) and cholesterol levels between the groups. DAS-28, HAQ-DI, CRP, ESR, and disease duration were not significantly correlated with FRS. Conclusion: For patients who have inflammatory arthritis, new risk score calculation that consists of other disease-specific risk factors, in addition to traditional ones, is needed.

Anahtar Kelimeler:

Key words: Rheumatoid arthritis, cardiovascular risk, functional insufficiency, disease activity

The correlation between cardiovascular risk and functional disability and disease activity in the patients with rheumatoid arthritis

Keywords:

Key words: Rheumatoid arthritis, cardiovascular risk, functional insufficiency, disease activity,

PDF

___

Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2746–9.
Warrington KJ, Kent PD, Frye RL, Lymp JF, Kopecky SL, Goronzy JJ. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005; 7: 984–91.
Davis JM, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 2008; 58: 2603–11.
Lipsky PE. Romatoid Artrit. Sağlıker Y, translator from English. Harrison İç Hastalıkları Prensipleri, 3. Cilt. İstanbul: Nobel Kitabevi; 2004. p.1928–37 (in Turkish).
Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43: 1791–6.
Brown MA, Newton JL, Wordsworth BP. Connective tissue disease. In: Genetics for Rheumatologists - The Molecular Genetic Basis of Rheumatological Disorders. 1st ed. London: Remedica Publishing; 2002. p.2–20.
Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121: 641–7.
National Heart, Lung and Blood Institute and Boston University. Epidemiological Background and Design: The Framingham Heart Study. Available at http://www.framinghamheartstudy. org/. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 249–56.
Smolen JS, Breedveld FC, Schiff MH. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42: 244–57.
Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T et al. Increased coronary-artery atherosclerosis in RA: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52: 3045–53.
Kelt I, Uren N. Cardiovascular risk in rheumatoid arthritis. Br J Cardiol 2009; 16: 113–5.
PİAR. Sigara alışkanlıkları ve sigara ile mücadele kampanyası araştırma raporu. İstanbul: PİAR; 1988 (in Turkish).
Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, HİrslevPetersen K, Luukkainen RK, Combe B et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10: 30.
Graf J, Scherzer R, Grunfeld C. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009; 4: 6242.
Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–8.
Radovitz BJ, Popa-Diaconu DA, Popa C. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1271–6.
Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology Oxford 2003; 42: 607–13.
Turesson C, Matteson EL. Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 2007; 19: 190–6.
Westhovens R, Nijs J, Taelman V, Dequeker J. Body composition in rheumatoid arthritis. Br J Rheumatol 1997; 36: 444–8.
Brady SRE, De Courten B, Reid CM, Cicuttini FM, de Courten MP, Liew D. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol 2009; 36: 34–40.
Van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68: 1395–400.
Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 2001; 44: 1467–9.
Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study. Arthritis Rheum 2005; 52: 2293–9.
Naz SM, Farragher TM, Bunn DK, Symmons DP, Bruce IN. The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008; 58: 985–9.
Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7.
Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010; 28: 53–64.
Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374–7.
Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al. Anti-tumor necrosis factor-treatment improves endothelial function in patients with RA. Circulation 2002; 106: 2184–7.
Crilly MA, Clark HJ, Kumar V, Scott NW, MacDonald AG, Williams DJ. Relationship between arterial stiffness and Stanford Health Assessment Questionnaire disability in rheumatoid arthritis patients without overt arterial disease. J Rheumatol 2010; 37; 946–52.
Özaydın M. Postoperative atrial fibrillation, oxidative stress, and inflammation Turk J Med Sci 2011; 41: 755–9.
Bostan M, Şatıroğlu Ö, Uydu HA, Çiçek Y, Çanga A, Karadağ Z et al. Distribution of coronary artery risk factors: a regional analysis. Turk J Med Sci 2011; 41: 317–24.
Öztaş YE, Özdöl Ç, Karaca L. Plasma LDL subtype distribution in patients with or without coronary stenosis. Turk J Med Sci 2011; 41: 959–64.